| Popis: |
Regina Carmen Espósito,1 Paulo Jose de Medeiros,2 Fernando de Souza Silva,3 Antonio Gouveia Oliveira,4 Cícero Flávio Soares Aragão,4 Hugo Alexandre Oliveira Rocha,5 Sueli Aparecida Moreira,6 Valéria Soraya de Farias Sales1 1Department of Clinical and Toxicology Analysis, Clinical Immunology Laboratory, Postgraduate Program in Development in Innovation Technogical in Medicines, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; 2Division of Urology, Department of Integrated Medicine, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; 3Urology Clinic University of Hospital Onofre Lopes, Federal University of Rio Grande do Norte, Natal, RN, Brazil; 4Department of Pharmacy, Federal University of Rio Grande of Norte, Natal, Rio Grande do Norte, Brazil; 5Department of Biochemistry, Biosciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; 6Hideas Feeding and Nutritional Security Research Group, Biosciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil Background: Metabolic syndrome (MetS) is an aggregation of risk factors associated with increased incidence of cardiovascular disease, type 2 diabetes mellitus, and all-cause mortality. Information on MetS prevalence is scarce in the northeast region, Brazil. This study aims to estimate the prevalence of MetS according to different diagnostic criteria in a community sample of men during the November Blue Campaign living in the metropolitan area of Natal, Rio Grande do Norte, Brazil. Methods: This is a cross-sectional study on 500 men aged 40 years or older invited by the Blue November Campaign of 2015, an awareness program aimed at the prevention of male diseases. The evaluation included blood pressure, anthropometric measurements (weight, height, and waist circumference), fasting blood glucose, and blood lipid profile. The diagnosis of MetS was made according to the criteria of International Diabetes Federation (IDF)/American Heart Association (AHA)/National Heart, Lung, and Blood Institute (NHLBI), IDF, and National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATPIII). Results: The prevalence was high by considering the following three criteria: IDF/AHA/NHLBI (66.8%), IDF (60.0%), and NCEP-ATPIII (46.4%). Concordance between diagnostic criteria measured by the kappa statistic (k) was excellent between IDF/AHA/NHLBI and IDF (k=0.85, P |
